Statistically significant dose-dependent reduction in tumor volume across all treatment groups compared to control in an ovarian xenograft model. Complete elimination of tumor and 100% survival observed in the group receiving optimal treatment regimen.
Toronto, Canada, April 6, 2023 — Alpha Cancer Technologies Inc. (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced details from the company’s abstract published as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting will take place in Chicago from June 2-6, 2023.
View Full Press Release